Detalhe da pesquisa
1.
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
J Clin Oncol
; 35(6): 591-597, 2017 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28199818